Aptevo Therapeutics Inc. (APVO) Free cash flow 2016–2023
Aptevo Therapeutics Inc. (APVO) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$11.8MFY2023 · since FY2016: -$38.4M → -$11.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -$11.8M | +45.9% |
| FY2022 | -$21.7M | +0.1% |
| FY2021 | -$21.8M | +26.1% |
| FY2020 | -$29.5M | +32.0% |
| FY2019 | -$43.4M | +17.9% |
| FY2018 | -$52.8M | -19.8% |
| FY2017 | -$44.1M | -14.8% |
| FY2016 | -$38.4M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More APVO financial trends
APVO RevenueAPVO Net incomeAPVO Net marginAPVO Gross profitAPVO Gross marginAPVO Operating incomeAPVO Operating marginAPVO Operating cash flowAPVO Capital expendituresAPVO Return on equityAPVO Stock buybacksAPVO Dividends paidAPVO Total assetsAPVO Total liabilitiesAPVO Shareholders’ equityAPVO overview →